Emergencies in haematology: tumour lysis syndrome

Urshila Durani, William J. Hogan

Research output: Contribution to journalReview articlepeer-review


Tumour lysis syndrome (TLS) is a significant complication of haematologic malignancies and their management. The syndrome consists of laboratory abnormalities either alone (laboratory TLS) or with clinical sequelae including renal failure, seizures, and arrhythmias (clinical TLS). Clinical TLS is a predictor for worse overall morbidity and mortality in cancer patients, but can be prevented. Thus, accurate prognostication is critical to appropriate management of patients at risk for TLS, and incorporates both disease factors (tumour type and burden) and patient factors (baseline renal insufficiency or hyperuricaemia). Strategies to prevent TLS include hydration and allopurinol in low- and intermediate-risk patients and rasburicase in high-risk patients.

Original languageEnglish (US)
Pages (from-to)494-500
Number of pages7
JournalBritish journal of haematology
Issue number4
StatePublished - Feb 1 2020


  • leukemia
  • lymphoma
  • renal failure
  • tumor lysis syndrome

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Emergencies in haematology: tumour lysis syndrome'. Together they form a unique fingerprint.

Cite this